CAR33 treatment led to complete ablation of CD33⁺ events while sparing CD33^null cells. (A) Depletion of CD33⁺ granulocytes in the PB in both treatment animals. Scaled proportion of CD33⁺ events by flow cytometry with absolute cell counts by complete blood counts (CBC). (B) Measured CD33 editing in bulk WBCs before and immediately after CAR33 treatment. Editing measured by ddPCR (A17039) and MiSeq (A18038). (C) Proportions of CD33⁺ and CD33⁻ granulocytes after CAR33 treatment. Granulocyte identity and CD33 positivity determined by flow cytometry and scaled using absolute cell counts from CBC.